Mizuho lowered shares of Fortrea (NASDAQ:FTRE – Free Report) from a neutral rating to an underperform rating in a research note issued to investors on Wednesday, MarketBeat reports. Mizuho currently has $19.00 price target on the stock, up from their prior price target of $16.00.
Other equities research analysts have also issued reports about the stock. Citigroup boosted their price objective on shares of Fortrea from $22.00 to $27.00 and gave the company a “buy” rating in a report on Friday, October 30th. Evercore reissued an “outperform” rating on shares of Fortrea in a research report on Wednesday, July 29th. Robert W. Baird set a $23.00 target price on Fortrea in a research note on Thursday, July 30th. Truist Financial lifted their price target on Fortrea from $26.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Zacks Research cut Fortrea from a “hold” rating to a “strong sell” rating in a research report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Fortrea currently has a consensus rating of “Hold” and an average target price of $24.23.
Check Out Our Latest Research Report on Fortrea
Fortrea Stock Up 0.7%
Fortrea (NASDAQ:FTRE – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. The business had revenue of $691.50 million for the quarter, compared to analyst estimates of $671.57 million. Fortrea had a negative net margin of 2.58% and a positive return on equity of 13.98%. Analysts anticipate that Fortrea will post 0.86 EPS for the current year.
Hedge Funds Weigh In On Fortrea
Institutional investors have recently bought and sold shares of the business. Allworth Financial LP raised its position in shares of Fortrea by 22.3% during the 2nd quarter. Allworth Financial LP now owns 3,923 shares of the company’s stock worth $68,000 after purchasing an additional 716 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Fortrea by 9.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 10,936 shares of the company’s stock valued at $103,000 after buying an additional 953 shares in the last quarter. Ethic Inc. lifted its stake in Fortrea by 7.4% in the 3rd quarter. Ethic Inc. now owns 14,928 shares of the company’s stock valued at $298,000 after buying an additional 1,029 shares in the last quarter. Financial Management Professionals Inc. acquired a new stake in Fortrea in the 3rd quarter worth about $30,000. Finally, Amundi boosted its holdings in Fortrea by 20.2% in the 1st quarter. Amundi now owns 12,490 shares of the company’s stock worth $118,000 after buying an additional 2,101 shares during the last quarter.
Fortrea Company Profile
Fortrea Holdings Inc. is a global contract research organization that provides clinical development and patient access services to pharmaceutical, biotechnology and medical device companies. The company supports the development of medicines and medical products from early research through later-stage clinical trials and post-approval studies. Its services include clinical trial planning and management, clinical pharmacology, patient recruitment and engagement, data management, regulatory support and related consulting.
Further Reading
- Five stocks we like better than Fortrea
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.
